share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K:重大事件
美股SEC公告 ·  2024/06/22 04:33

Moomoo AI 已提取核心信息

Allarity Therapeutics received a notice from Nasdaq Listing Qualifications Staff on June 18, 2024, citing non-compliance with the minimum bid price requirement. The company failed to maintain a closing bid price above $1 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).The company plans to request a hearing before the Nasdaq Hearings Panel to maintain its listing status while working towards compliance. This hearing request will temporarily stay the suspension of trading and delisting of the company's common stock. Trading will continue on the Nasdaq Capital Market at least until the Panel makes its decision.However, there is no guarantee that the Panel will grant Allarity's request for continued listing or suspension of delisting. The company must demonstrate its ability to meet Nasdaq's listing requirements to maintain its position on the exchange.
Allarity Therapeutics received a notice from Nasdaq Listing Qualifications Staff on June 18, 2024, citing non-compliance with the minimum bid price requirement. The company failed to maintain a closing bid price above $1 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).The company plans to request a hearing before the Nasdaq Hearings Panel to maintain its listing status while working towards compliance. This hearing request will temporarily stay the suspension of trading and delisting of the company's common stock. Trading will continue on the Nasdaq Capital Market at least until the Panel makes its decision.However, there is no guarantee that the Panel will grant Allarity's request for continued listing or suspension of delisting. The company must demonstrate its ability to meet Nasdaq's listing requirements to maintain its position on the exchange.
2024年6月18日,Allarity Therapeutics公司收到纳斯达克上市资格工作人员的通知,由于其普通股买盘价格连续30个工作日低于每股1美元的最低要求,公司不符合纳斯达克上市规则5550(a)(2)。公司计划请求纳斯达克听证委员会的听证会,以寻求继续上市,同时努力恢复符合要求。提出听证请求会推迟交易暂停和可能的股票退市,直到委员会做出决定。Allarity Therapeutics公司警告称,没有保证委员会会允许公司继续在纳斯达克资本市场上市。
2024年6月18日,Allarity Therapeutics公司收到纳斯达克上市资格工作人员的通知,由于其普通股买盘价格连续30个工作日低于每股1美元的最低要求,公司不符合纳斯达克上市规则5550(a)(2)。公司计划请求纳斯达克听证委员会的听证会,以寻求继续上市,同时努力恢复符合要求。提出听证请求会推迟交易暂停和可能的股票退市,直到委员会做出决定。Allarity Therapeutics公司警告称,没有保证委员会会允许公司继续在纳斯达克资本市场上市。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息